Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-26T06:01:10.676Z Has data issue: false hasContentIssue false
  • English
  • Français

Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review

Published online by Cambridge University Press:  21 May 2015

Jeremy M. Wojtowicz ,
Mark C. Yarema  and
Paul M. Wax
Jeremy M. Wojtowicz*
Affiliation:
Department of Family Medicine, University of Calgary, Calgary, Alta. Department of Emergency Medicine, University of Calgary, Calgary, Alta.
Mark C. Yarema
Affiliation:
Department of Family Medicine, University of Calgary, Calgary, Alta. Department of Emergency Medicine, Calgary Health Region, Calgary, Alta.
Paul M. Wax
Affiliation:
Section of Toxicology, University of Texas Southwestern, Dallas, Tex.
*
Department of Emergency Medicine, Room C231 Foothills Medical Centre, 1403-29 St. NW, Calgary AB T2N 2T9; [email protected]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

1,4-Butanediol (1,4-BD) is an industrial solvent that is metabolized to gamma-hydroxybutyrate (GHB), a gamma-aminobutyric acid agonist and central nervous system depressant. GHB and its analogues are popular drugs of abuse. Withdrawal from these agents is characterized by autonomic instability and altered mental status. We report a case of withdrawal from 1,4-BD lasting 6 days and complicated by new onset of seizures and rhabdomyolysis. In addition, we conducted a systematic review of the English literature pertaining to withdrawal from GHB, 1,4-BD and gamma-butyrolactone (GBL). Data collected from source articles included last use prior to symptom onset, clinical features on presentation, duration of symptoms and outcome. Twenty-seven studies with 57 episodes of withdrawal were included. Thirty-six cases (63%) involved GHB, 3 cases (5%) involved 1,4-BD and 18 (32%) involved GBL. The most common patient symptoms were tremor (67%), hallucinations (63%), tachycardia (63%) and insomnia (58%). Seizures and rhabdomyolysis each occurred in 7% of cases, but only 1 death occurred. Emergency physicians must consider withdrawal from these agents when patients present with clinical features suggestive of a sedative-hypnotic withdrawal syndrome.

Résumé

RÉSUMÉ

Le butane-1,4-diol (BD-1,4) est un solvant industriel qui se métabolise en 4-hydroxybutanoate (GHB), un agoniste de l'acide 4-aminobutanoïque et un dépresseur du système nerveux central. Le GHB et ses analogues sont des drogues populaires faisant l'objet d'abus. Le sevrage de ces agents se manifeste par une instabilité autonome et un état mental altéré. Nous présentons un cas de sevrage de BD-1,4 ayant duré 6 jours et ayant été compliqué par une nouvelle apparition de convulsions et de rhabdomyolyse. Nous avons en outre réalisé une revue systématique de la littérature anglaise portant sur le sevrage du GHB, du BD-1,4 et du gamma-butyrolactone (GBL). Les données recueillies des articles sources incluaient des renseignements sur la dernière utilisation avant la survenue de symptômes, les manifestations cliniques à l'arrivée des patients à l'urgence, la durée des symptômes et les résultats. La revue portait sur 27 études décrivant 57 épisodes de sevrage. Trente-six cas (63 %) étaient liés au GHB, 3 cas (5 %) au BD-1,4 et 18 (32 %) au GBL. Les tremblements (67 %), les hallucinations (63 %), la tachycardie (63 %) et l'insomnie (58 %) étaient les symptômes les plus courants observés chez les patients. Les convulsions et la rhabdomyolyse se sont manifestées respectivement dans 7 % des cas, mais seulement 1 décès a eu lieu. Lorsqu'un patient présente des manifestations cliniques évoquant le syndrome de sevrage de sédatifs hypnotiques, les médecins d'urgence devraient considérer la possibilité de sevrage de ces agents.

Keywords

1,4-butanediolgamma-hydroxybutyrategamma-butyrolactonesubstance withdrawal syndrome
Type
Case Report • Rapport de cas
Information
Canadian Journal of Emergency Medicine , Volume 10 , Issue 1 , January 2008 , pp. 69 - 74
Copyright
Copyright © Canadian Association of Emergency Physicians 2008

References

1. Dyer, J. Gamma-hydroxybutyrate: a health food product producing coma and seizure like activity. Am J Emerg Med 1991;9: 321–4.Google Scholar
2. Zvosec, DL, Smith, SW, McCutcheon, JD, et al. Adverse events, including death, associated with the use of 1,4-Butanediol. N Engl J Med 2001;344:87–94.Google Scholar
3. Takahara, J, Yunoki, S, Yakushiji, W, et al. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977;44:1014–7.Google Scholar
4. Controlled Drugs and Substances Act. 1996, c. 19 Available: http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en (accessed 2007 Nov 21).Google Scholar
5. Dyer, JE, Roth, B, Hyma, BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37:147–53.Google Scholar
6. Craig, K, Gomez, HF, McManus, JL, et al. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18:65–70.Google Scholar
7. Catalano, MC, Glass, JM, Catalano, G, et al. Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001;42:83–8.Google Scholar
8. Greene, T, Dougherty, T, Rodi, A. Gamma-butyrolactone (GBL) withdrawal presenting as acute psychosis. J Toxicol Clin Toxicol 1999;37:651.Google Scholar
9. Herold, AH, Sneed, KB. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 2002;15:161–3.Google Scholar
10. McDaniel, CH, Miotto, KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001;33:143–9.Google Scholar
11. Mycyk, MB, Wilemon, C, Aks, SE. Two cases of withdrawal from1,4-butanediol use. Ann Emerg Med 2001;38:345–6.Google Scholar
12. Reeves, J, Duda, R. GHB/GBL intoxication and withdrawal: a review and case presentation. Addictive Disorders & Their Treatment 2003;2:25–8.Google Scholar
13. Schneir, AB, Ly, BT, Clark, RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-Butanediol. J Emerg Med 2001;21:31–3.Google Scholar
14. Sharma, AN, Nelson, L, Hoffman, RS. Severe gamma butyrolac-tone withdrawal. J Toxicol Clin Toxicol 2000;38:535.Google Scholar
15. Sivilotti, MLA, Burns, MJ, Aaron, CK, et al. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001;38:660–5.Google Scholar
16. Wojtowicz, JM, Yarema, MC, Wax, PM. A case of prolonged withdrawal from use of 1,4-butanediol complicated by seizure and rhabdomyolysis [abstract]. CJEM 2006;8:195.Google Scholar
17. Tarabar, AF, Nelson, LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004;23:45–9.Google Scholar
18. Goldfrank, LR, Flomenbaum, NE, Lewin, NA, et al. Goldfrank’s toxicologic emergencies. 7th ed. New York (NY): McGraw-Hill; 2002.Google Scholar
19. Ford, MD, Ling, LJ, Delaney, KA, et al. Clinical toxicology. 1st ed. Philadelphia (PA): W.B. Saunders; 2001.Google Scholar
20. Haddad, LM, Shannon, MW, Winchester, JF. Clinical management of poisoning and drug overdose. 3rd edition. Philadelphia (PA): W.B. Saunders; 1997.Google Scholar
21. Gonzalez, A, Nutt, DJ. Gamma hydroxyl butyrate abuse and dependency. J Psychopharmacol 2005;19:195–204.Google Scholar
22. Miotto, K, Darakjian, J, Basch, J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001;10:232–41.Google Scholar
23. Mullins, ME, Fitzmaurice, SC. Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med 2001;20:418–9.Google Scholar
24. Garvey, R, Fitzmaurice, B. Withdrawal delirium with dance drug ‘liquid ecstasy’ (GHB). Ir J Psych Med 2004;21:73–5.Google Scholar
25. Dyer, JE, Andrews, KM. Gamma hydroxybutyrate withdrawal. J Toxicol Clin Toxicol 1997;35:553–4.Google Scholar
26. Dyer, JE, Roth, B, Hyma, BA. GHB withdrawal syndrome: 8 cases. J Toxicol Clin Toxicol 1999;37:650.Google Scholar
27. Galloway, GP, Frederick, SL, Staggers, F Jr. Physical dependence on sodium oxybate. Lancet 1994;343:57.Google Scholar
28. Chew, G, Fernando, A. III. Epileptic seizure in GHB withdrawal. Australas Psychiatry 2004;12:410–1.Google Scholar
29. Chin, RL. A case of severe withdrawal from gamma-hydroxybutyrate. Ann Emerg Med 2001;37:551–2.Google Scholar
30. Addolorato, G, Caputo, F, Capristo, E, et al. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin Neuropharmacol 1999;22:60–2.Google Scholar
31. Bowles, TM, Sommi, RW, Amiri, M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001;21:254–7.Google Scholar
32. Friedman, J, Westlake, R, Furman, M. ‘Grievous bodily harm:’ gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996;46:469–71.Google Scholar
33. Galloway, GP, Frederick, SL, Staggers, FE Jr, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997;92:89–96.Google Scholar
34. Glasper, A, McDonough, M, Bearn, J. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal a case report. Eur Addict Res 2005;11:152–4.Google Scholar
35. Hernandez, M, McDaniel, CH, Costanza, CD, et al. GHB-induced delirium: a case report and review of the literature on gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998;24:179–83.Google Scholar
36. Hutto, B, Fairchild, A, Bright, R. gamma-Hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000;157:1706.Google Scholar
37. Mahr, G, Bishop, CL, Orringer, DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001;42:439–40.Google Scholar
38. Miglani, JS, Kim, KY, Chahil, R. Gamma-hydroxybutyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 2000;22:213–6.Google Scholar
39. Price, G. In-patient detoxification after GHB dependence. Br J Psychiatry 2000;177:181.Google Scholar
40. Rosenberg, MH, Deerfield, LJ, Baruch, EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003;29:487–96.Google Scholar
41. Slagel, B, Kingstone, E, Bhalerao, S. Gamma hydroxybutyrate withdrawal in an orthopedic trauma patient. Can J Psychiatry 2003;48:131–2.Google Scholar
42. Trendelenburg, G, Heinz, A, Strohle, A. Gamma-hydroxybutyrate dependence with social phobia. Am J Psychiatry 2004;161:375–6.Google Scholar
43. Hoes, MJ, Vree, TB, Guelen, PJ. Gamma-hydroxybutyric acid as hypnotic: clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980;6:93–9.Google Scholar
44. Wong, CGT, Chan, KFY, Gibson, KM, et al. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev 2004;23:3–20.Google Scholar
45. Snead, OC III, Gibson, KM. Gamma-hydroxybutyric acid. N Engl J Med 2005;352:2721–32.Google Scholar
46. Rang, HP, Dale, MM, Ritter, JM. Anxiolytic and hypnotic drugs. In: Pharmacology. 4th ed. Edinburgh (UK): Churchill Livingstone; 1999. p 531–2.Google Scholar
47. McDonough, M, Kennedy, N, Glasper, A, et al. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75:3–9.Google Scholar